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Abstract 
Transthyretin (TTR) amyloidosis, the most frequent form of hereditary amyloidosis, is 
caused by dominant mutations in the TTR gene. More than 100 mutations have been 
identified. Clinical manifestations of TTR amyloidosis are usually induced by extracellular 
amyloid deposition in several organs. The major neurological manifestation is motor-
sensory neuropathy associated with dysautonomic impairment. Here, we describe a 
63-year-old man who came to our institution due to a suspected motor neuron disease. 
During a 4-year follow-up period, he underwent extensive clinical examination, 
electromyographic studies, sural nerve biopsy and TTR gene analysis by direct 
sequencing. Despite the predominant motor involvement, the detailed clinical 
examination also showed some mild sensory and dysautonomic signs. In addition, his 
clinical and family history included multiorgan disorders, such as carpal tunnel 
syndrome, as well as conditions with cardiac, renal, eye, and hepatic involvement. The 
sural nerve biopsy disclosed amyloid deposition, and the sequence analysis of the TTR 
gene detected a heterozygous Tyr78Phe substitution. The TTR gene variant found in our 
patient had only been described once so far, in a French man of Italian origin presenting 
with late-onset peripheral neuropathy and bilateral carpal tunnel syndrome. The 
predominant motor involvement presented by our patient is an uncommon occurrence 
and demonstrates the clinical heterogeneity of TTR amyloidosis. 
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Introduction 
Hereditary amyloidosis represents a clinically and genetically heterogeneous group of 
autosomal dominant inherited diseases characterized by the deposit of insoluble variants 
of physiological proteins in the extracellular matrix [1]. Mutated transthyretin (TTR), 
formerly called prealbumin and encoded by a gene on chromosome 18, is the most 
frequent protein implicated, whereas apolipoprotein A1, lysozyme, fibrinogen, gelsolin, 
amyloid-β and cystatin C are much more uncommon [2]. TTR is a tetrameric serum 
protein involved in the transport of serum thyroxine and retinol-binding protein 
synthesized in the liver and, minimally, in the choroid plexus. Its variation enables the 
dissociation of tetrameric TTR, which increases the concentration of aberrant 
amyloidogenic monomers. TTR amyloidosis is characterized by slowly progressive 
peripheral sensorimotor and autonomic neuropathy [1, 3] as well as cardiomyopathy [4], 
nephropathy, vitreous opacities, and central nervous system involvement [5]. Portugal 
and Japan are the countries with the largest endemic foci [6]. 
In this study, we report a 63-year-old man who carries a missense mutation in the TTR 
gene and presented with rapidly progressive axonal motor neuropathy, clinically 
resembling a motor neuron disease, with subclinical signs of sensory involvement. 
Case Report 
The patient first came to our attention when he was 63 years old. He presented with increasing 
weakness of the lower limbs, muscle fatigue, and dysphagia, which began at the age of 59 years. His 
neurological symptoms worsened over the years, resulting in a greater difficulty in climbing the stairs 
and standing up from a chair. 
He had a positive cardiological history that included supraventricular arrhythmia (treated with 
ablation of the arrythmogenic focus) and atrial fibrillation (which resolved after pharmacological 
therapy). In addition, he had a right eye cataract, Paget’s disease, chronic renal failure due to 
glomerulonephritis, gastroesophageal reflux, and hepatic steatosis. At 45 and 55 years of age, the patient 
underwent surgical decompressions for bilateral carpal tunnel syndrome with a secondary lesion of the 
right median nerve. His family history was positive for cardiomyopathy, type II diabetes mellitus, 
hypertension, cancer, and Parkinson’s disease. Neuromuscular disorders were not evident in the family 
history. The patient’s father died at 63 years of age due to renal failure, and his mother died at 69 years 
of age due to ovarian neoplasm. He had 1 brother and 1 sister, both of whom had bilateral carpal tunnel 
syndrome and myopia; the brother also had cataracts and the sister underwent surgery for uterine 
neoplasm. 
The patient was admitted to another hospital, where he underwent several investigations. An 
electromyogram (EMG) detected an axonal motor neuropathy with minimal sensory impairment; the 
amplitude of the sensory nerve action potential was decreased (4 μV right; 6 μV left). A muscle biopsy, 
performed on the quadriceps femoris, showed a neurogenic pattern characterized by high size 
variability, with several atrophic fibers and fiber type II grouping. Connective tissue increase, cellular 
infiltrates as well as necrotic fibers were absent. A brain MRI and cerebrospinal fluid analysis showed 
normal results. Anti-GM1 IgM antibodies were mildly increased (1/640). 
In the following months, the patient exhibited a severe and rapid progression of the motor 
impairment of the 4 limbs, characterized by muscle atrophy and fasciculation, without comparable 
clinical defect of the sensory component. Since the subclinical sensory impairment, only detectable with 
electrophysiology, was interpreted as incidental finding, the patient was diagnosed with probable 
amyotrophic lateral sclerosis (ALS), although his clinical presentation was more suggestive of 
progressive muscular atrophy; he was therefore referred to our motor neuron disease center.  
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The patient underwent an extensive clinical assessment, comprehensive of family and personal 
history data recording, complete neurological examination, and muscle strength evaluation using the 
Medical Research Council and ALS Functional Rating Scale. 
Our neurological examination revealed bulbar signs such as tongue atrophy and fasciculation, nasal 
voice, and dysarthria. The strength of the trunk and upper proximal limb muscles was normal. The 
patient presented with some difficulty in digital skills, hand weakness with diffuse fasciculation, and 
atrophy of the right arm. He had bilateral mild proximal muscle weakness in the lower limbs, with a 
particular atrophy in the distal regions (right > left). He was able to walk on his own, albeit on tiptoe. 
Ubiquitous absence of osteotendon reflexes was detected. A sensory deficit was observed only in the first 
3 fingers of the right hand. His ALS Functional Rating Scale score was 31. 
The EMG was repeated and showed a pattern characterized by electroneurographical findings 
compatible with motor-sensory neuropathic involvement. At nerve conduction study, the tibial 
posterior nerve showed a reduced compound muscle action potential amplitude (0.9 and 0.5 mV) and a 
reduced nerve conduction velocity (NCV; 36.5 and 36.4 m/s). The sensitive NCV of the sural nerve was 
reduced bilaterally (36.2 and 33.3 m/s), as were the NCV and sensitive action potential amplitude of the 
ulnar (46.6 m/s) and radial (50 m/s) nerves. The concentric electric needle examination demonstrated 
neurogenic signs predominantly at the lower limbs, with fibrillation potentials and motor unit action 
potentials characterized by prolonged amplitude and duration. A paraspinal muscle EMG was also 
performed and revealed the presence of fibrillation. 
Since the patient had a sporadic occupational exposure to polychlorinated biphenyls, he was also 
examined by a specialist in occupational medicine who excluded any possible link between the patient’s 
polyneuropathy and work. Other genetic causes of motor neuron syndromes were also excluded. The 
superoxide dismutase 1 gene was screened as the first gene in our familial ALS assessment protocol, and 
the valosin-containing protein gene was analyzed because of the comorbid Paget’s disease. Both analyses 
showed negative results. 
A more detailed medical history investigation revealed the presence of dysautonomia presenting as 
erectile dysfunction that was not previously reported. Neither the patient’s history nor clinical 
examination revealed any other dysautonomic symptoms. For this reason, no additional autonomic 
tests were performed, but specific tests to examine the sensory and dysautonomic involvement will be 
considered during follow-up. The remote and familial history and the findings of dysautonomia and 
mild sensory impairment associated with systemic aspects (above-mentioned cardiac, ocular and renal 
features) suggested revising the patient’s diagnosis, and amyloid etiopathogenesis was considered. 
A periumbilical fat biopsy was performed and showed no amyloid deposition. We decided to 
perform a TTR gene molecular analysis and detected the presence of a heterozygous missense mutation 
(p.Tyr78Phe; c.293A>T according to Ensembl genome browser ID OTTHUMT00000254948) (fig. 1). 
Samples from the patient’s parents were not available for further investigation because both were 
deceased and other siblings were not available for analysis. The pathogenic role of this mutation was 
confirmed through a sural nerve biopsy analysis, which showed a mild axonal neuropathic pattern 
characteristic of amyloidosis and demonstrated a reduced myelinization that was more evident in semi-
thin sections, with conserved bimodal distribution. Endoneurial connective tissue was increased, blood 
vessels were normal, and cellular infiltrates were absent. The quantitative analysis showed a fiber density 
of 1,475 nerve fibers/mm
2 (normal value according to the age: 4,800 ± 1,000). A teasing technique 
showed a normal aspect in 49% of the fibers, total demyelinization in 41%, and axonal degeneration in 
6%; 2% presented with segmental demyelinization or remyelinization, respectively (fig. 2). 
The disease was confirmed through specific staining with Congo red, which revealed strongly 
positive deposits in several capillary walls that appeared as apple-green birefringence when examined 
under polarized light. 
Given that liver transplantation is still the only recognized therapy for TTR polyneuropathy, this 
possibility was proposed to our patient, who is now waiting for transplantation.  
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Discussion 
Mutations in the TTR gene are among the most frequent causes of hereditary 
autosomal dominant amyloidosis and are mainly responsible for familial amyloid 
polyneuropathy (FAP), which is characterized by predominant sensorimotor and 
autonomic involvement due to endoneurial and polyvisceral extracellular deposition of 
amyloid substance [7]. Interestingly, motor function is preserved until the sensory 
neuropathy has advanced considerably. 
Here, we describe the case of a patient with predominant motor involvement, leading 
to a diagnostic hypothesis of motor neuron disease. The major clinical features of this 
patient were distal limb paralysis, atrophy, fasciculations, dysphagia, and dysarthria. The 
sensory and autonomic deficits were minimal and were only identified after accurate 
electroneurographic study and complete clinical data collection. These aspects, in 
association with the patient’s past medical history of carpal tunnel syndrome as well as the 
presence of some systemic defects such as renal impairment, cardiac fibrillation, and 
cataracts, led to the suspicion of amyloidosis. 
Molecular analysis revealed the presence of the heterozygous missense mutation 
p.Tyr78Phe in the TTR gene. The pathogenicity of this mutation and the link between 
amyloid deposition and polyneuropathy were confirmed histologically by the sural nerve 
biopsy, which demonstrated mild peripheral axonal neuron sufferance with positive 
birefringent deposits at Congo red staining. The amyloidogenic properties of the 
Tyr78Phe mutation of the TTR gene have also been demonstrated by Redondo et al [8], 
who showed that the substitution of residue 78 led to a changed tetrameric structure that 
might represent an early intermediate in the fibrillogenesis pathway. 
Although the p.Tyr78Phe mutation is rare, it has been described once before in a 
78-year-old French man of Italian origin who was affected with late-onset peripheral 
neuropathy in the lower limbs, bilateral carpal tunnel, and skin amyloidosis [9]. More 
than 100 pathogenic mutations leading to misfolding and formation of amyloid deposits 
have been detected in the TTR gene [10]. These mutations are mainly single nucleotide 
substitutions with an autosomal pattern of transmission but variable penetrance [11]. 
Among them, the substitution of a methionine at codon 30 (p.Val30Met) was the first to 
be described [12] and so far remains the most frequent, especially in Portugal, North 
Sweden, and Japan. Some mutations are associated with a specific clinical presentation, 
such as predominant cardiomyopathy [13]. Other variants can present a wide clinical 
interfamilial variability [14], probably due to epigenetic and environmental factors. 
Usually, FAP is progressing faster than in our patient, and even if there are no studies to 
date correlating TTR mutations and survival, the very rare mutation in our patient could 
be related to a disease form with longer evolution. 
The peculiar aspect in this case was the unusual manifestation of polyneuropathy with 
a predominant motor involvement and only minimal and late-onset sensory and 
dysautonomic signs. Sensory and autonomic involvement can be subtly but definitely 
present in amyloidosis, and new investigation tools may help to test sensitive and 
dysautonomic symptoms in TTR mutation polyneuropathy and to identify the amyloid 
pathologic substrate. The value of standard quantitative autonomic and sensation tests in 
detecting, characterizing, and quantifying the severity of TTR amyloid polyneuropathy 
has recently been assessed [15]. In addition, the quantitative assessment of cutaneous  
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nerve fibers can be employed as an indicator of the severity of neuropathy [16]. 
Identifying a specific causative amyloid protein from nerves and other tissues is often 
difficult but important in diagnosis and treatment. The possibility of distinguishing the 
specific type of amyloidosis from nerve biopsies combining laser microdissection and 
mass spectrometric-based proteomic analysis has also been recently described. This new 
proteomic approach can promote both diagnostic and research efforts in amyloidosis 
[17]. Some of these methods are still experimental and were not applied in our case, but 
they may be considered for the assessment and follow-up of TTR patients. 
The above-mentioned atypical manifestation of FAP has only been described in a 
single case by Quattrini et al. [18]. Because of this finding, amyloid polyneuropathy 
should be considered as an alternative diagnosis of motor neuron disease, especially in the 
presence of systemic symptoms, such as carpal tunnel syndrome and cataract, renal, heart, 
or skin involvement. The clinical phenotypic heterogeneity of TTR mutations and the 
predominant motor or sensory/dysautonomic pattern can be explained by the complex 
multifactorial mechanisms that regulate amyloid fibrillogenesis in FAP, such as the 
intrinsic conformation of the TTR fibril protein, its concentration, the structural effects of 
the TTR mutation, microenvironments of the lysosome, proteolytic processing, amyloid 
cofactors, and tissue-specific determinants [19]. 
We underscore that the negative results from the periumbilical fat and muscle biopsies 
does not exclude the diagnosis. In fact, in our patient the periumbilical fat biopsy did not 
reveal amyloid deposition, and the muscle biopsy must be completed with specific 
methods, such as Congo red staining, which are not routinely used. 
The recognition of amyloid etiologies in patients affected with predominant motor 
polyneuropathy with few sensory signs is fundamental. In fact, the molecular definition of 
this disease can help in genetic counseling, because the mutation is inherited in an 
autosomal dominant manner [6]. 
Furthermore, the early diagnosis of amyloid neuropathy allows the timely starting of 
potential therapies, such as liver transplantation. 
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Fig. 1. Sequence analysis showing the nucleotide substitution c.10783C>T, which leads to the 
heterozygous missense mutation Tyr78Phe in exon 1. 
 
 
 
Fig. 2. a, b Light microscopy: Gomori’s trichrome stain of 3 nerve fascicles shows moderate to severe 
loss of myelinated fibers (a, ×100; b, ×400). c Semithin cross-section confirms severe reduction of 
myelinated fiber density (toluidine blue stain, ×400). d Deposition of amyloid identified by Congo red 
(×200). 
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